OrphoMed
is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders... Read moreOrphoMed
is a biopharmaceutical company that develops dimer therapies for visceral hypersensitivity and hypermotility in gastrointestinal disorders... Read more
News
Jan 04, 2022
MarketScreener
OrphoMed: OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
Apr 14, 2021
MarketScreener
OrphoMed: OrphoMed's ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
Jan 26, 2021
MarketScreener
OrphoMed: OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
Jun 02, 2020
MarketScreener
OrphoMed: OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
Mar 31, 2020
MarketScreener
OrphoMed: OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
Feb 19, 2020
BioPortfolio
OrphoMed: OrphoMed to Present Phase 1 Results of ORP101 at Digestive Disease Week 2020
Jan 07, 2020
BioPortfolio
OrphoMed: OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP101 for Treatment of IBSD
Dec 18, 2018
4-traders
OrphoMed: OrphoMed Announces Formation of Scientific Advisory Board
Apr 25, 2018
WardsAuto
OrphoMed: FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
Jan 31, 2018
Market Cheetah
OrphoMed: OrphoMed to Present at the 2018 BIO CEO & Investor Conference
OrphoMed Competitors
1
2
3
4
5
6
7
8
9
10